• Dr. Mohammed Al-Omran co-inventor of U.S. patented method to prevent, treat heart disease

    Click on image to read full story...

  • KING SAUD UNIVERSITY, LI KA SHING INSTITUTE COLLABORATION A SUCCESS STORY

    Click on image to read full story...

Subodh Verma – FRCSC, MD, PhD, MSc

 

Basic Science Research Lead, KSU Program
 
Scientist, Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael’s Hospital
 
Associate Professor, Department of Surgery, University of Toronto
 
Canada Research Chair in Atherosclerosis, Department of Surgery, University of Toronto
 
Director of Traineeship in Atherosclerosis, Division of Cardiac Surgery, St. Michael’s Hospital
 
                      
                                                                                                 BIOGRAPHY
 
Dr. Subodh Verma is an expert on vascular biology, endothelial dysfunction and atherosclerosis and has published extensively on all of these subjects. As the undergraduate pharmacy gold medalist, he went on to obtain a M.Sc. and a Ph.D. in cardiovascular pharmacology at theUniversityofBritish Columbia. He then pursued an MD degree and a post-doctoral fellowship in Cardiology at theUniversityofCalgary. Following his residency training in cardiac surgery, he was appointed Associate Professor of Surgery and Pharmacology at theUniversityofToronto. In 2007, Dr. Verma was named the Canada Research Chair in Atherosclerosis, in 2009 he was placed on the India Abroad Power List and in 2010, he was recognized as one of Canada’s Top 40 under 40.

Dr. Verma oversees an active research team comprising Research Associates, Research Technicians, Surgeon/Physician-Scientistsin-training and Postdoctoral Fellows. The core of Dr. Verma’s research program focuses on the role of risk factors on endothelial function, vascular homeostasis and cardiac function. These research endeavours are currently supported by a Canadian Foundation for Innovation and Ontario Research Funds grant, two Canadian Institutes of Health Research grants and four Heart & Stroke Foundation grants in addition to grants from the Canadian pharmaceutical industry. Dr. Verma’s research laboratory employs innovative basic and translational approaches to study mechanisms through which inflammatory cytokines, such as C-reactive protein, adiponectin, and other agents such as angiotensin I converting enzyme 2, visfatin and neuregulin, are linked to vascular diseases. More recently, in an attempt to study basic and translational atherosclerosis by drawing parallels to the cancer and stem cell literature, Dr. Verma is spearheading groundbreaking “out-of-the-box” investigations pivoting around the cardiovascular effects of BRCA-1, a genome-wide gatekeeper ofDNArepair typically associated with breast, ovarian and pancreatic cancer. This extremely fruitful venture has culminated in the filing of a U.S. Provisional Patent.

Dr. Verma is also actively involved in several ongoing provincial, national and international research trials that cover the gamut of novel surgical procedures, clinical assessments and management as well as epidemiology. He is the co-Medical Director of the not-for-profit Canadian Cardiovascular Research Network that pursues the mandate of improving cardiovascular care inCanadathrough multi-prong research and promotion of inter-disciplinary and academiaindustry interactions. Dr. Verma has published over 200 peer-reviewed papers and over 400 abstracts, with several papers appearing in NEJM, Nature, Circulation and Circulation Research.

PUBLICATIONS
 
Please find below a list of selected publications that Dr. Verma has authored and or been involved in through the KSU Program. For additional publications, please click on the PubMed link.
 
  1. Al-Omran M, Singh, KK, Shukla, PC, Quan, A, Lovren, F, Pan, Y, Wolfstadt, JI, Gupta, M, Leong-Poi, H, Teoh, H and Verma, S. Anti-ERBB2 induces cardiomyocyte death and p53 activation.  Am J Physiol Heart Circ Physiol. 2011 (In Press).
  2. Al-Omran M, Verma S, Lindsay TF. Suboptimal Use of Risk Reduction Therapy in Patients with Peripheral Arterial Disease: A Major Teaching Hospital Experience.  Annals of Saudi Medicine 2011; 31(4):371-5.
  3. Singh K, Shukla P, Quan A, Lovren F, Pan Y, Wolfstadt J, Gupta M, Al-Omran M, Leong-Poi H, Teoh H, Verma S. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochemical and Biophysical Research Communications 2011;411(2):421-6
  4. Al-Mubarak HA, Alamri TM, Aljabab SA, Atteya M, Quan A, Teoh H, Shukla PC, Verma S, Aldahmash A, Aljabri B, Napoli C, Al-Omran M. Effects on duration of post-operative ischemia and patterns of blood flow recovery in different conditions of mouse hind limb ischemia. Vasc Cell. 2011 Jun 14;3(1):14.
  5. Shukla PC, Singh KK, Quan A, Al-Omran M, Teoh H, Lovren F, Cao L, Rovira II, Pan Y, Brezden-Masley C, Yanagawa B, Gupta A, Deng C-X, Coles JG, Leong-Poi H, Stanford WL, Parker TG, Schneider MD, Finkel T, Verma S.  BRCA1 is an Essential Regulator of Heart Function and Survival following Myocardial Infarction.  Nature Communications (In press)
  6. Singh K, Shukla P, Quan A, Lovren F, Pan Y, Wolfstadt J, Gupta M, Al-Omran M, Leong-Poi H, Teoh H, Verma S. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochemical and Biophysical Research Communications 2011;411(2):421-6
  7. Singh KK, Shukla PC, Quan A, Lovren F, Pan Y, Wolfstadt JI, Gupta M, Al-Omran, M, Leong-Poi H, Teoh H, Verma S. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death.  Biochem Biophys Res Commun: 2011: 411: pp 421-6.
  8. Singh, KK, Shukla, PC, Al-Omran M, Quan, A, Lovren, F, Pan, Y, Wolfstadt, JI, Gupta, M, Leong-Poi, H, Teoh, H and Verma, S. BRCA2 deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure. Journal of Biological Chemistry (JBC). 2011 (In Press).
  9. Lovren F, Al-Omran M,  Pan Y, Quan A, Singh K, Shukla P, Gupta M,  Al-Omran M, Teoh H, Verma S.  Adropin is a Novel Regulator of Endothelial Function. Circulation 2010:122(11 Suppl):S185-92
  10. Lovren F, Al-Omran M,  Quan A, Singh K, Shukla P, Teoh H, Verma S. Adiponectin Primes Human Monocytes into Alternative Anti-inflammatory M2 Macrophages. Am J Physiol Heart Circ Physiol 2010: 299(3):H656-63.
  11. Lovren F, Pan Y, Quan A, Szmitko PE, Singh KK, Shukla PC, Gupta M, Chan L, Al-Omran M, Teoh H, Verma S.  Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages.  Am J Physiol: 2010: 299: pp H656-H663.
  12. Lovren F, Pan Y, Shukla PC, Quan A, Teoh H, Szmitko PE, Peterson MD, Al-Omran M, Verma S.Visfatin (nicotinomide phosphoribosyltransferase/pre-B cell colony-enhancing factor) activates eNOS via Akt andMAP kinases and improves endothelial cell function and angiogenesis in-vitro and in-vivo. Am J Physiol Endocrinol Metab. 2009: 296(6):E1440-E1449
  • Click on image to view video

  • Click Image to View Information Booklet

%d bloggers like this: